Clearmind Medicine announces first US base for its phase

TEL AVIV, Israel / VANCOUVER, Canada, May 22, 2023 (Globe Newswire) — Biotechnology company Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or “Company”) ), which is focused on the discovery and development of novel psychedelic-derived therapeutics to address major undertreated health problems, today announced Phase I/ Announced selection of first US site for Phase IIa clinical trial. Treatment of alcohol use disorders (“AUD”). The Yale School of Medicine’s Department of Psychiatry is the first US-based clinical site to participate in the Company’s First In Human (FIH) clinical trial.

The site will be led by Dr. Anahita Basil Nia, an expert on substance abuse, including alcohol abuse. After completing a psychiatric residency at Mount Sinai Beth Israel and an Addiction Psychiatry Fellowship at the Icahn School of Medicine at Mount Sinai West, New York, she joined the Yale School of Medicine in 2018 as an Assistant Professor of Psychiatry. was appointed to

Dr. Adi Zurof Shani, Chief Executive Officer of ClearMind, Inc. said, “We are honored to welcome the Department of Psychiatry at Yale University School of Medicine as part of our clinical trial. We are global pioneers in psychedelic research. We believe that this collaboration with will be a further validation of psychedelic research.” Our innovative drug candidate as a potential treatment for alcohol use disorders. ”

Clearmind recently announced that a Phase I/IIa clinical trial of CMND-100 has been approved by the Israel IMCA Center’s Ethics Committee (equivalent to an Institutional Review Board). The CM-CMND-001 clinical trial is a multinational, multicenter, single and multiple dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects .

“As successfully demonstrated in previous preclinical studies, we believe CMND-100 has the potential to be a game changer in the treatment of addiction and mental health concerns,” said Zurov. added Dr. Shani. “With an extensive IP portfolio and an award-winning advisory board of renowned psychiatrists and researchers from around the world, we are confident in our unique treatment model. As a self-administered, non-addictive prescription drug that is not dependent on any other therapeutic regimen, it is expected to provide immediate therapeutic benefit.”

In clinical trials, oral capsules are administered once daily for 10 consecutive days. Patients report drinking patterns and alcohol (and tobacco) cravings during the trial.

The primary endpoint of this study is to find single- and repeated-dose tolerated doses of CMND-100 in healthy subjects and patients with AUD, and to characterize safety and pharmacokinetics/pharmacodynamics (PK/PD). The secondary endpoint is to assess her effectiveness of CMND-100 in reducing drinking patterns and cravings in individuals with moderate to severe her AUD.

Dr. Zurov Shani said, “Her research has focused on addiction and mental health disorders, and she is particularly interested in the biological effects of acute and chronic stress on the development of substance use disorders.” Dr. Bashir Nir said he was best suited for the task.

almost clear mind Medicine Co., Ltd.

Clearmind is a psychedelic pharmaceutical biotechnology company focused on the discovery and development of new psychedelic-derived therapeutics to solve a wide range of underserved health problems, including alcohol use disorders. Its primary purpose is to research, develop, and attempt to commercialize psychedelic-based compounds as regulated drugs, foods, or supplements.

The company’s intellectual portfolio currently consists of 14 patent families. The company intends to seek additional patents for its compounds whenever warranted, and will remain opportunistic in acquiring additional intellectual property to build its portfolio.

Clearmind shares are listed on the NASDAQ and Canadian Stock Exchange under the symbol “CMND” and on the Frankfurt Stock Exchange under the symbol “CWY”.

For more information, please visit or contact us at:

PR for investors

Phone: (604) 260-1566

United States:

General inquiries

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” and similar expressions or variations of such words is intended to identify forward-looking statements in For example, we use forward-looking statements when discussing our collaboration with clinical trials and the potential therapeutic benefits of our product candidates. Forward-looking statements are based on management’s current expectations, beliefs and projections rather than historical facts, many of which, by their nature, are inherently uncertain. Any such expectations, beliefs and projections are expressed in good faith. However, there is no guarantee that management’s expectations, beliefs or projections will be achieved, and actual results may differ materially from those expressed or indicated in the forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual performance or results to differ materially from those expressed in forward-looking statements. For a more detailed description of the risks and uncertainties affecting us, please refer to our reports filed from time to time with the Securities and Exchange Commission (“SEC”). Our Annual Report on Form 20-F filed with the SEC on February 6, 2023. Forward-looking statements speak only as of the date the statements are made. Except to the extent required by applicable securities laws, we make no forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information. We undertake no obligation to update any statements relating to If we update one or more forward-looking statements, it should not be inferred that we will make additional updates to that or any other forward-looking statement. References and links to websites are provided as a convenience and the information contained in such websites is not incorporated by reference into this press release. Clearmind is not responsible for the content of his website of third parties.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *